# RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer

> **NCT02466906** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Hospital of the Chinese Academy of Military Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** rhGM-CSF
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02466906
- **Lead sponsor:** The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2020-06
- **Final completion:** 2020-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02466906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02466906, "RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02466906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*